Disorders Of Serum Minerals Flashcards
Ca above………….. are symptomatic
13 mg/dL
Differential Diagnosis
Hyperproteinemia
• Parathyroid hormone–related hypercalcemia
– Primary hyperparathyroidism
– Tertiary hyperparathyroidism
– Familial hypocalciuric hypercalcemia
• Non parathyroid hormone–mediated hypercalcemia
– Malignancy-associated hypercalcemia (PTHrP)
– Granulomatous diseases
– Milk-Alkali syndrome
– Hyperthyroidism, Parenteral nutrition, Immobilization,meditations.
Renal impairment due to hypercalcemia
• Afferent arteriolar vasoconstriction»_space; ↓GFR,
• Diabetes insipidus
Cardiac impairment due to hypercalcemia
Shortening of the QTc interval, widened QRS, bradycardia
Hyperparathyroidism
• Primary hyperparathyroidism:
• Secondary hyperparathyroidism:
• Tertiary hyperparathyroidism:
85% single parathyroid adenoma
vitamin D deficiency, calcium deficiency, or chronic kidney disease
chronic renal failure
Primary para hyperparathyroidism
• Asymptomatic
➢ Osteoporosis, bone pain, nephrolithiasis,
– BMD is relatively preserved at the spine, lower at the hip, particularly low at the
⅓ radius. (This is because the ⅓ radius is a predominantly cortical.)
• Classic skeletal manifestations: osteitis fibrosa cystica , brown tumors
Familial hypocalciuric hypercalcemia (FHH):
*Autosomal dominant
* inactivating mutations of the calcium sensing receptor (CaSR)at PTH
• Hypercalcemia is typically mild, in the range of 11 to 12 mg/dL
➢ Abnormal calcium receptors are also expressed in the kidney
• Asymptomatic, Do not develop adverse sequelae
• homozygous patients usually develop severe hypercalcemia in infancy
Malignancy-associated hypercalcemia
=A Non-PTH-mediated hypercalcemia
Among hospitalized patients (in known advanced malignancy)
• Approximately 50% of patients die within 30 days of developing malignancy-
associated hypercalcemia
• Tumors that commonly cause hypercalcemia include breast, renal, squamous cell,
ovarian carcinomas, multiple myeloma, and lymphoma
Malignancy-associated hypercalcemia
=A Non-PTH-mediated hypercalcemia
- Humoral hypercalcemia of malignancy (HHM) (~ 80% )
- local tumor invasion of the skeleton
- 1α-hydroxylase enzyme
Humoral hypercalcemia of malignancy (HHM) (~ 80% )
Results from excessive secretion of parathyroid hormone–related protein (PTHrP)
• PTHrP acts on the same receptor as PTH and can induce similar systemic effects.
• Reductions in the levels of PTH, 1,25-dihydroxyvitamin D3, and serum phosphorus
local tumor invasion of the skeleton
Breast cancer or a hematologic neoplasm such as multiple myeloma, leukemia, or lymphoma.
• Local factors secreted: PTHrP, RANKL, interleukin-6, …
• Hypercalcemia, hyperphosphatemia, ↓ PTH, ↓ PTHrP and ↓ 1,25(OH)2D
1α-hydroxylase enzyme
Secretion of 1,25(OH)2D by lymphomas and dysgerminomas.
• The increased 1,25(OH)2D leads to intestinal calcium hyperabsorption as well as
bone resorption.
• This condition is mechanistically similar to the hypercalcemia that occurs in
granulomatous disease
Granulommatous disease
including sarcoidosis, tuberculosis, and fungal infections
➢ 1α-hydroxylase enzyme
• hypercalcemia and hyperphosphatemia
Milk-Alkali syndrome
Ingestion of very large quantities of calcium carbonate or other calcium-containing
antacids
• Triad of hypercalcemia, metabolic alkalosis, and acute kidney injury
• Calcium intake in patients typically exceeds 4 g/day
• Drugs that may cause hypercalcemia include
Thiazide diuretics
lithium
Vitamins D